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1. Introduction     
Unprecedented progress in the field of genetics and genomics has offered the opportunity to 
explore the human brain to a larger extend than ever before. Especially the acquisition, 
coding, storage, recall, and decoding of information that form the response to an ever-
changing environment are very active areas of research. The sequencing of the entire human 
genome and the description of inter-individual genomic variations ranging from single base 
pair changes to large-scale structural variations allow to link individual differences in 
cognitive ability to genomic changes, therefore advancing our understanding of information 
processing, storage, learning and memory (Subramanian et al., 2001).  
In recent years, a major advancement in cognitive neuroscience in recent years has been the 
discovery of germline mutations in genes of the ras-induced mitogen-activated protein 
kinase (RAS/MAPK) signalling cascade, a unique signalling pathway transmitting signals 
from cell surface receptors to the nucleus with subsequent changes in gene transcription. A 
group of individuals affected with developmental disorders and variable degrees of 
cognitive impairment, who shared additional abnormalities in other body systems, have 
been instrumental to this process (Tidyman & Rauen, 2008; Tidyman & Rauen, 2009). 
Individuals with Noonan syndrome, LEOPARD syndrome, Costello syndrome, Cardio-
Facio-Cutaneous syndrome, and Neurofibromatosis (NF1) have clinical symptoms in a 
number of body systems, including variable abnormalities in learning and memory. Cardiac 
malformations, skeletal abnormalities, skin manifestations, an increased risk for cancer, and 
characteristic facial features are often found in individuals affected with these rare genetic 
syndromes. Even though each syndrome represents a unique clinical entity that can be 
differentiated based on the combination of clinical symptoms and disease course, they also 
share a number of overlapping symptoms suggesting that these syndromes could be 
causally related disorders. The majority of individuals affected with these syndromes were 
found to have rare mutations in a variety of genes that could be linked to the RAS/MAPK 
signalling pathway. The identification of unique mutations in each disorder ultimately shed 
some light on the pathophysiology of the neuro-cardio-facial-cutaneous syndrome family. 
These rare Mendelian developmental disorders are instructive example for the successful 
application of classical genetic linkage studies, positional focused sequencing approaches, 
and candidate gene approaches in combination with detailed phenotyping that eventually 
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led to the discovery of a neurophysiological system that might play a key role in cognitive 
and developmental processes.     
Developmental disorders with cognitive disabilities in general are common, affecting about 
1-2% of the population; however, the identification of the underlying genetic cause is 
hindered by the heterogeneity of the disorders. Many different genetic and environmental 
causes could potentially lead to the rather non-specific symptom of cognitive impairment. 
Genetic mutations that have been identified in some affected individuals are usually rare 
and may constitute new changes that have not been inherited from the parents. This makes 
the identification of underlying genetic factors difficult. Large-scale genetic mapping 
techniques, such as genome-wide association studies or linkage analysis in a large number 
of families are impractical under these scenarios. In the neuro-cardio-facio-cutaneous 
syndromes, it took the careful delineation of the clinical phenotype of the patients, prior 
knowledge of signalling pathways, and knowledge of genomic variance to link the 
phenotype to specific genomic variants. Researchers focussing on x-linked mental 
retardation took a different approach (Tarpey et al., 2009). Direct sequencing of all coding 
regions on the X chromosome in a heterogeneous group of families, in which mental 
retardation was inherited in an X-linked mode, led to the discovery of new genes involved 
in mental retardation. Nevertheless, much more inter-individual genomic variability was 
discovered than ever expected and a large proportion of this variability was found not to be 
related to mental retardation.   
The progress in the field of mental retardation research can be helpful in understanding 
what to expect and how to approach other common mental disorders such as schizophrenia 
and mood disorders. In these conditions progress has been less impressive. Developmental 
syndromes, non-syndromic mental retardation, and psychiatric disorders share many 
common features, sometimes even overlapping symptoms. In this article, we will try to 
explore and compare approaches to brain function in different but intimately related 
disciplines of research and to open up ways for new approaches to the complexity of the 
brain. Great progress has been made in understanding the function of the brain and much 
more will be learned now that direct sequencing of single individuals is within reach as a 
cost-effective approach to the study of inter-individual genomic variation. However, it also 
has become clear that an overly simplistic understanding of the relationship between 
genomic variation and physiological consequences is questionable (Raymond et al., 2009). 
2. The RAS/MAPK signalling cascade 
The identification of mutations in proteins linked to the RAS/MAPK cascade in individuals 
with severe impairment of cognitive functions has led to the discovery of a signal pathway 
that appears to play a central role in cognitive development (Figure 1) (Aoki et al., 2008). 
Through cascading protein phosphorylations, information is transmitted from the cell 
surface to the cell nucleus leading to long lasting changes in cell metabolism and cell growth 
(Hancock, 2003). A key component of the RAS/MAPK signalling pathway is a family of 
small G-protein coupled molecules known as the RAS kinase family. These molecules, 
which have been implemented in cancer (Gibbs et al., 1984), transition between two 
functional states, an inactive form, which is bound to guanine-dinucleotide-phosphate 
(GDP) and an active form, which is bound to guanine-trinucleotide-phosphate (GTP). The 
transition between the inactive and the active state is facilitated by guanine-nucleotide-
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exchange factors (GEFs), whereas the transition from the active state back to the inactive 
state is catalyzed through GTPase-stimulating proteins (GAPs). The RAS GTPase activity 
can be stimulated among others by tyrosine kinase-coupled growth factor receptors. The 
tyrosine kinase recruits a docking protein, for example growth factor receptor-bound 
protein 2 (GRB2) or Src-homology-2-containing tyrosine phosphatase (SHP-2), which is the 
protein product of the gene tyrosine-protein phosphatase non-receptor type 11 (PTPN11). 
The tyrosine kinase/SHP-2 complex subsequently activates the GEF proteins, which then 
transform RAS from its inactive to its active state. Activation of RAS proteins leads to the 
recruiting of Raf kinases, for example CRAF, encoded by the gene v-raf-1 murine leukemia 
viral oncogene homologue 1 (RAF1) and v-raf murine sarcome viral oncogene homologue 
B1 (BRAF) to the membrane. This event leads to the subsequent phosphorylation of the first 
member of the RAS/MAPK cascade, which starts a phosphorylation cascade of kinases, 
including the dual specificity mitogen-activated protein kinase kinase 1/2 (MEK1/MEK2), 
the MAP kinase kinase (MAP2Ks), and the extracellular signal-regulated kinase 1/2 
(ERK1/ERK2), also known as MAP kinases (MAPKs). Activated ERK1 and ERK2 
phosphorylate both nuclear and cytosolic substrates, connecting the cell surface receptors to 
nuclear transcription factor complexes and signalling molecules in the cytoplasm (Yoon & 
Seger, 2006). The ribosomal S6-kinase 2 (RSK2) is one of those proteins that connect the 
RAS/MAPK cascade to the cAMP response-element (CRE) binding (CREB) protein, a 
transcriptional regulator. Subsequent changes in gene expression lead to long lasting 
alterations in cell metabolism, cell growth and mobility. In the brain, alterations in synaptic 
strength, changes in the electric properties of the cell membrane, increase in the 
responsiveness to neurotransmitters, and even changes in the number and size of synapses 
have been observed (Weeber et al., 2002). In addition to tyrosine-kinase bound growth factor 
receptors, this cascade can also be activated through other mechanisms. Phospholipase C 
(PLC) and phosphokinase C (PKC) can activate RAS and provide links to neurotransmitter 
pathways of metabotropic glutamate receptors, acetylcholine (ACH), and serotonin 
receptors.      
3. The neuro-cardio-facio-cutaneous syndrome family 
Several excellent recent reviews of the neuro-cardio-facio-cutaneous syndromes and their 
underlying genetic risk factors have recently been published (Tidyman & Rauen, 2008; 
Tidyman & Rauen, 2009). Therefore, only a brief overview summarizing the clinical features 
and mutations found in these syndromes will be given in this text. 
3.1 Noonan syndrome 
Noonan syndrome (MIM 163950) is an autosomal dominant disorder with characteristic 
craniofacial features, congenital heart defects, and short stature. Ophthalmological 
abnormalities, musculoskeletal and cutaneous anomalies are common in these patients as 
well (Noonan, 1968; Shaw et al, 2007). Impairment in cognitive functions, such as learning 
and memory, is a variable symptom and occurs only in about 25-30% of individuals with 
this syndrome (Lee et al., 2005). Genetic linkage studies have mapped this disorder to a 
region on chromosome 12. Subsequently, mutations in the coding region of the gene 
PTPN11, located on chromosome 12q24.13, were found in patients with Noonan syndrome 
by positional sequencing of candidate genes in the region (Tartaglia et al., 2001). PTPN11 
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encodes the protein tyrosine phosphatase SHP-2, which is an initiator of the RAS/MAPK 
signalling cascade (Figure 1). Mutations in PTPN11 led to structural and functional changes 
in SHP-2, and therefore, an involvement of the gene in the pathophysiology of Noonan 
syndrome appeared likely. Soon, however, it became clear that missense mutations in this 
gene could explain only a portion of the cases clinically diagnosed with Noon syndrome 
indicating genetic heterogeneity (Tartaglia et al., 2001). Subsequently, mutations in the 
coding regions of other genes involved in the RAS/MAPK pathway were found. 
Sequencing of candidate genes identified mutations in the genes son of sevenless homolog 1 
(SOS1) (Roberts et al., 2007; Tartaglia et al., 2007), v-raf-1 murine leukaemia viral oncogene 
homolog 1 (Raf1) (Pandit et al., 2007; Razzaque et al., 2007), and Kirsten rat sarcoma viral 
oncogene homolog (KRAS) (Schubbert et al., 2006; Zenker et al., 2007). Even though the most 
frequent genetic cause of Noonan syndrome is a mutation in the gene PTPN11, individual 
mutations are rare and scattered throughout several coding regions of the gene prohibiting a 
simple predictive genetic test. All known mutations affect the stability of the inactive form 
of the protein leading to a gain of function and increased signalling activity through the 
RAS/MAPK phosphorylation cascade. A simple genotype/phenotype correlation has not 
been feasible. Especially cognitive impairment is variable in this syndrome and not linked to 
a specific mutation. A recent comparison of patients with mutations in the genes PTPN11 
and SOS1, however, indicated that learning disabilities were absent in patients with 
mutations in SOS1 (Pierpont et al., 2009), whereas cognitive impairments were common 
among individuals with PTPN11 mutations and those with unknown mutation status. In 
addition to the effect of specific mutations, individual specific genetic background, gene-
gene interactions, and compensatory mechanisms might account for the variability in the 
phenotype (Tartaglia et al., 2002).  
3.2 LEOPARD syndrome 
LEOPARD syndrome (MIM 151100) is an allelic disorder to Noonan syndrome, because it is 
caused by mutations in the same genes, PTPN11 and RAF1 (Digilio et al., 2002; Legius et al., 
2002; Pandit et al., 2007). In LEOPARD syndrome the functional consequence of mutations 
in PTPN11  is a loss of function instead of the gain of function usually found in Noonan 
syndrome. LEOPARD syndrome is characterized by cutaneous changes (Lentigines), EKG 
abnormalities, ocular abnormalities, pulmonary valve stenosis, abnormal genitalia, 
retardation of growth, and deafness. The clinical phenotype of the affected individuals is 
quite similar to Noonan syndrome despite opposite effects of the mutations on the function 
of the protein.  
3.3 Costello syndrome 
In 1971, Costello described a new genetic syndrome with characteristic facial features, 
ectodermal anomalies, especially nasal papillomas, and developmental delay (Costello, 
1971; Costello, 1977). Subsequently, extensive reviews have summarized findings in 
similarly affected individuals and have delineated the clinical phenotype now known as 
Costello syndrome (MIM 218040). Even though this genetic syndrome is clearly distinct 
from Noonan syndrome, both syndromes share some overlapping features (Hennekam, 
2003). Individuals affected with Costello syndrome have more severe cognitive impairment 
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than individuals affected with Noonan syndrome (Axelrad et al., 2007; Delrue et al., 2003). 
Search for mutations in genes of the RAS/MAPK signalling pathway led to the 
identification of a variety of mutations in the gene v-Ha-ras Harvey rat sarcoma viral 
oncogene homologue (HRAS) (Aoki et al., 2005; van Steensel et al., 2006; Zampino et al., 
2007). The functional consequences of these mutations are increased HRAS activity and an 
increase in signalling through the RAS/MAPK pathway. The phenotype in patients with 
Costello syndrome is variable even with identical mutations in HRAS (Gripp et al., 2006; 
Kerr et al., 2006).  
3.4 Cardio-facio-cutaneous syndrome  
Cardio–facio–cutaneous (CFC) syndrome (MIM 214080) is characterized by distinct facial 
features resembling Noonan syndrome; ectodermal abnormalities, musculo-skeletal 
findings, and cardiac malformations. Ocular symptoms are frequently present as well 
(Reynolds et al., 1986, Borradori & Blanchet-Bardon, 1993; Wieczorek et al., 1997; Young et 
al., 1993; Grebe & Clericuzio, 2000; Sabatino et al., 1997; Herman & McAlister, 2005; Chan et 
al, 2002). Many features of this syndrome are overlapping with Noonan syndrome causing 
diagnostic uncertainty especially in young infants. However, in contrast to Noonan 
syndrome, cognitive impairment is universally present in patients with CFC syndrome 
(Yoon et al., 2007). Ultimately, the identification of a wide variety of mutations in the gene 
BRAF helped to clarify the diagnostic uncertainties (Rauen, 2006; Schulz et al., 2008; Narumi 
et al., 2007; Nava et al., 2007; Gripp et al., 2007). Mutations in three other related genes, 
MAP2K1, MAP2K2 (Rodriguez-Viciana et al., 2006) and Ki-ras2 Kisten rat sarcoma viral 
oncogene homologue (KRAS) (Schubbert et al. 2006; Niihori et al., 2006) have also been 
identified in patients with CFC syndrome.  
3.5 Neurofibromatosis    
Neurofibromatosis (NF1) is clinically quite distinct from the neuro-cardio-facio-cutaneous 
syndrome family. NF1 occurs in about 1 in 4,000 birth and is characterized by the 
development of benign neurofibromas of the peripheral nervous system and skin 
discolorations (Riccardi, 1981). Gliomas of the peripheral nerves and skeletal dysplasias can 
occasionally occur. Mild cognitive impairment manifested as learning disability is present in 
about 40% to 60% of patients. Neurofibromatosis is characterized by incomplete penetrance, 
which means that even if an individual carries a disease-causing mutation the expression of 
the disease phenotype is highly variable. The identification of mutations in the gene 
neurofibromin shed light on possible underlying pathomechanisms in this disorder 
(Viskochil et al., 1990; O'Connell et al., 1992). Neurofibromin is a GAP protein, which 
transforms activated RAS protein back to the inactive state. The neurofibromin gene is 
highly expressed in the developing brain of the embryo. In the adult brain, expression can 
be found in the Purkinje cells, pyramidal cells, Schwann cells and oligodendrocytes. The 
RAS/MAPK signalling pathway plays a critical role in memory formation and learning 
through long lasting alterations of gene expression in neuronal cells. Therefore, learning 
deficits could be explained by alterations in this important signalling pathway, however, 
learning disabilities in patients with Neurofibromatosis are variable (Costa et al., 2001; Costa 
et al., 2002). Neurofibromin knock-out mice have confirmed learning deficits in mice due to 
RAS hyperactivity. Treatment with a farnesyl-transferase inhibitor could reverse some of the 
effects of the mutation in mice (Costa et al., 2002). 
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Fig. 1. The Neuro-Cardio-Facio-Cutaneous syndrome family and its relationship to 
mutations in proteins of the RAS/MAPK signalling cascade. Solid lines indicate associations 
to mutations in the proteins involved in the signalling cascade. Arrows indicate activating 
and inactivating events. Abbreviations: Ca2+, ionic calcium; ACH, Acetylcholine; CaMk, 
Calcium-calmodulin kinase; PLC, Phospholipase C; PKC, Phosphokinase C; SHP-2, Src 
homology 2 domain-containing-transforming protein; NF1, neurofibromatosis type 1; GDP, 
guanine dinucleotide phosphate; GEF, guanine-nucleotide-exchange factor; SOS1, son of 
sevenless homologue 1; GTP, guanine trinucleotide phosphate; GAP, GTPase-stimulating 
proteins; cAMP, cyclic adenosine monophosphate; PKA, Protein kinase A; CRAF, RAF1 v-
raf-1 murine leukemia viral oncogene homolog 1;  BRAF, v-raf murine sarcome viral 
oncogene homologue B1; MEK, mitogen-activated protein kinase kinase; MAPK, mitogen-
activated protein kinase; ERK, Extracellular signal-regulated kinase; RSK2, ribosomal S6-
kinase 2; CREB, CRE binding protein; CBP, CREB binding protein; CRE, cAMP response-
element; CFC, cardio-facio-cutaneous. 
3.7 Coffin-Lowry syndrome 
Coffin-Lowry syndrome (MIM 303600) is a severe mental retardation syndrome with 
mutations in the ERK/CREB pathway, which is activated by the RAS/MAPK signalling 
cascade (Figure 1). This rare mental retardation disorder is characterized by an abnormal 
gait, facial abnormalities including protruding forehead, wide nose, and irregular teeth. 
Individuals affected with this syndrome are often short with poor bone mineralization and 
underdevelopment of the musculature (Coffin et al., 1966; Lowry et al., 1971). Coffin-Lowry 
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syndrome is caused by a wide variety of mutations in the gene 90 kDa ribosomal S6 serin-
threonine kinase 2 (RSK2) located on chromosome Xp22.2 (Trivier et al., 1996). The spectrum 
of mutations includes splice site alterations, missense mutations, frame-shift alterations, and 
nonsense mutations. In the hippocampus, RSK2 phosphorylates and activates a number of 
nuclear proteins including CREB when activated by the ERK pathway (Jacquot et al., 1998; 
Xing et al., 1996). The RSK2 mutant mouse model resembles the Coffin-Lowry syndrome 
patients in that it shows marked deficits in motor development, coordination and spatial 
learning (Dufresne et al., 2001). 
 
Syndrome Gene Chromosome References 
Noonan syndrome PTPN11 12q24.13 Tartaglia et al., 2001 
 SOS1 2p22-p21 Roberts et al., 2007 
Tartaglia et al., 2007 
 RAF1 3p25 Pandit et al., 2007;  
Razzaque et al., 2007 
 KRAS 12p12.1 Schubbert et al., 2006;  
Zenker et al., 2007 
LEOPARD syndrome PTPN11 12q24.13 Digilio et al., 2002;  
Legius et al., 2002 
 RAF1 3p25 Pandit et al., 2007 
Costello syndrome HRAS 11p15.5 Aoki et al., 2005 
Cardio-facio-cutaneous 
syndrome 
BRAF 7q34 Rauen, 2006;  
Schulz et al., 2008; Narumi et 
al., 2007; Nava et al., 2007; 
Gripp et al., 2007 
 MAP2K1 15q22.31 Rodriguez-Viciana et al., 2006 
 MAP2K2 19p13.3 Rodriguez-Viciana et al., 2006 
 KRAS 12p12.1 Schubbert et al. 2006;  
Niihori et al., 2006 
Neurofibromatosis NF1 17q11.2 Viskochil et al., 1990 
Coffin-Lowry syndrome RSK2 Xp22.2 Trivier et al., 1996 
Rubinstein-Taybi syndrome CBP 16p13.3 Petrij et al., 1995 
    
Table 1. Genetic syndromes linked to genes in the RAS/MAPK pathway 
3.8 Rubinstein-Taybi syndrome 
A patho-mechanistically related disorder is the Rubinstein-Taybi syndrome (MIM 180849), a 
rare mental retardation syndrome occurring with a frequency of 1 in 125,000 live births. This 
autosomal dominant syndrome is characterized by distinct facial features, broad digits, 
angulated thumb, and blunted growth (Rubinstein & Taybi, 1963; Rubinstein, 1990). A 
variety of mutations in the gene transcriptional co-activator CREB-binding protein (CREB) 
have been identified in about 50% of patients (Petrij et al., 1995; Blough et al., 2000). CREB is 
located on chromosome 16p13.3. Mutations in this gene lead to protein changes that 
interfere with the binding of the transcription factor CRE through alterations in the 
chromatin structure within the promoter regions of the CRE regulated genes (Ogryzko et al., 
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1996). A mouse model carrying a dominant negative mutation in CREB displayed nearly all 
the features of Rubinstein-Taybi syndrome including deficits in long-term memory (Oike et 
al., 1999). The short-term memory was unimpaired.    
From this short overview of the neuro-cardio-facio-cutaneous syndromes is becomes clear 
that despite the common effect of increased signal transmission through the RAS/MAPK 
pathway, known mutations in component of this pathway lead to highly variable but 
distinct effect on the phenotype (Cesarini et al., 2009; Niihori et al., 2006; Rodriguez-Viciana 
et al., 2006; Garnett et al., 2005). The degree of cognitive impairment varies among 
syndromes, ranging from normal cognition in some cases of NF1 and Noonan syndrome to 
severe impairment in some cases of CFC-syndrome (Denayer et al., 2008). Overall, it can be 
said that mutations upstream of RAS seem to have less severe and more variable effects on 
cognitive impairment, whereas mutations in genes closer to the nucleus appear to have 
more detrimental effects. The success in identifying the underlying genetic mutations in 
these rare developmental Mendelian disorders was based on the presence of overlapping 
clinical phenotypes that pointed to possible candidate pathways. Common symptoms in 
many body systems allowed for the identification of groups of patients that were similar in 
their underlying pathophysiology and their genetic risk factors. Nevertheless, even in these 
homogeneous patient populations the genetic causes of the disorders were highly variable 
often involving several genes in the same pathway. Despite the success described above, the 
known mutations still explain only a portion of all the cases diagnosed with a particular 
syndrome on clinical grounds.  
X-linked mental retardation is another example of a condition that is characterized by 
extensive heterogeneity.  Only a percentage of cases can be explained by known genetic 
mutations. The absence of additional clinical features prohibits the sub-classification of 
patients into more homogeneous groups based on clinical presentation. The underlying 
heterogeneity of the genetic causes hinders the utilization of family-based linkage analyses 
and population-based association studies. Therefore, this disease category required a 
substantially different approach to the identification of the underlying genetic causes.        
4. X-lined mental retardation 
The frequency of mild to moderate mental disability defined as an IQ between 50 and 70 is 
about 2-3% in the general population; more severe intellectual impairment is found in 0.5 to 
1% of the population (Raymond, 2006). A significant portion of these disorders is inherited 
in an X-linked mode. About 80 genes located on the X-chromosome are known to be 
involved in mental retardation to date and many more are likely to be discovered. Many 
families have rare or even private disease-causing mutations that are not shared with other 
families and in a large percentage of these families mental retardation is the only symptom 
present. Direct re-sequencing approaches appear to be the only way to identify the 
underlying mutations in these families.   
A recent study involving patients affected with X-linked mental retardation used a large-
scale systematic re-sequencing approach to explore genomic variants present in the patients 
compared to their unaffected relatives. The study involved 208 families and focussed on the 
coding exons of all the genes located on the X-chromosome in a systematic approach 
(Tarpey et al., 2009). First, protein truncating changes in the coding regions of genes were 
analyzed since these changes could be expected to have the most severe consequences for 
the function of the protein. Using this approach mutations in four new genes were detected 
that were not previously known to be involved in mental retardation. A large number of 
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truncating mutations were identified. Overall, the majority of truncating mutations were not 
associated with disease status at all and even loss of about 1% of genomic material on the x-
chromosome was compatible with a normal phenotype. Truncating mutations associated 
with the phenotype were found in 10% of the genes located on the X-chromosome. 
However, each particular genomic change explained only a very small portion of mental 
retardation in the sample and in the majority of families the underlying genetic mutation 
could not be identified.   
In addition to truncating mutations, a large number of single nucleotide polymorphisms were 
found. Almost 2,000 single-nucleotide genomic variants were detected in the coding sequences 
of the genes alone. Almost half of these mutations were missense mutations leading to amino 
acid substitutions in the encoded proteins. Rare small insertions and deletions were also 
present. Nearly half of the mutations were found only once in the sample. Slightly more than 
half of the recurrent variants could be found in public databases for common genomic 
polymorphisms. On average, the genomic sequence of any two individuals differed by about 
100 variants in the coding regions alone. These results demonstrate the large amount of 
genomic variability that is present between any two individual genomes. Evaluation of the 
functional consequences of those genomic variants would be a daunting task. In addition it is 
likely that many variants with physiological consequences have been missed since introns of 
genes, the promoter regions or other non-coding regions have not even been sequenced in this 
study. These genomic regions are known to have important regulatory functions for gene 
expression and are even more variable than the coding regions themselves.  
In summary, it could be said that substantial genetic heterogeneity was found underlying X-
linked mental retardation. At least 10% of the genes located on the X-chromosome were 
involved, individual mutations were generally rare and each identified gene accounted only 
for a small portion of the cases. In addition to disease-causing mutations, a large number of 
rare non-synonymous mutations were identified that had no apparent effect on the 
phenotype. A surprising result of this study was that a large number of mutations 
interrupting the function of the gene were not causally related to mental retardation at all. In 
fact, loss of about 1% of genetic material on the X-chromosome was compatible with a 
normal phenotype. In this context it is important to stress that the identification of a rare 
truncating mutation in studies with large sample size will still require careful follow-up 
evaluation of the functional consequences and should not be considered as evidence for 
disease causation per se (Raymond et al., 2009). Despite its success, this study paints a 
daunting picture of the task ahead in the search for genomic variants underlying common 
complex disorders. Nevertheless, even the identification of rare mutations in a small 
number of cases might shed some light on underlying pathomechanisms of the disease.   
Schizophrenia is another disorder that is heavily researched, because improvement in the 
understanding of the underlying pathophysiology of this disorder promises to provide new 
treatment options. Schizophrenia shares many features with developmental disorders, as 
well as mental retardation syndromes including strong evidence for a genetic cause of the 
disease. Until now much uncertainty still exists regarding specific genetic variants that 
might contribute to the phenotype.    
5. Schizophrenia  
Schizophrenia is a common psychiatric disorder affecting about 0.5%-1% of the population. 
The clinical phenotype is characterized by dissociation of thoughts and emotions, distorted 
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perception of reality manifested as hallucinations and delusions, as well as emotional 
flattening over the disease course. The age of onset is usually in adolescence. Schizophrenia 
is often conceptualized as a complex disorder caused by multiple common genomic variants 
with small effect size in combination with environmental risk factors (Williams et al., 2009). 
Significant familiality and heritability have been demonstrated for this disorder (Cardno & 
Gottesman, 2000). Despite the fact that genetic risk factors play an important role in the 
manifestation of the disease, it has been difficult to replicate genome-wide significant 
linkage signals consistently (Williams et al., 2009). Even genome-wide association studies in 
thousands of individuals still left some doubt about underlying genetic risk factors (Allen et 
al, 2008; Need et al., 2009). The increase in power that was hoped for by collecting ever 
larger sample sizes might have been counteracted by increased heterogeneity of the disease 
(Craddock et al., 2008). If the same degree of heterogeneity is present in schizophrenia as it 
was found in developmental disorders or X-linked mental retardation, these results would 
not be surprising.  
Schizophrenia is often conceptualized as a developmental disorder. Candidate gene studies 
based on various hypotheses of disease pathology have been numerous with inconsistent 
results (Allen et al., 2008). In particular, these studies have been hindered by the fact that the 
symptoms of schizophrenia are rather non-specific and manifestations in other body 
systems are often lacking. Due to possible heterogeneity, replication of candidate gene 
association studies has been difficult and results have often not been convincing. Positional 
candidate gene studies that follow-up on significant family-based linkage studies have been 
more successful revealing several potential risk genes including neuregulin 1 (NRG1), 
dystrobrevin-binding protein 1 (DTNBP1), and D-amino acid oxidase inhibitor (DAOA), 
among others (Williams et al. 2009). However, overall mutations in these genes could 
explain only a very small percentage of cases.  
Recently, the focus of research has shifted from common single nucleotide polymorphisms 
to rare structural variants. This shift might have been inspired by the finding that about 10% 
of neuro-developmental disorders including autism and mental retardation are caused by 
non-inherited deletions and insertions of genetic material (Sebat et al, 2007; Autism Genome 
Project Consortium, 2007). Recent genome-wide studies in schizophrenia reported large 
multigenic deletions located on chromosomes 1q21.1 and 15q13.3, which were present in a 
very small number of individuals diagnosed with schizophrenia (International 
Schizophrenia Consortium, 2008; Stefansson et al., 2008; Need et al., 2009; Kirov G, 2009). In 
addition, exon-disrupting copy number variations have been identified in the gene NRXN1 
(Rujescu et al., 2009). Several of the deletions associated with schizophrenia had previously 
been associated with mental retardation, autism, ADHD, and other neuro-developmental 
disorders, including seizures (Mefford et al., 2008; Wassink et al., 2001; Sharp et al., 2008). 
Subsequent studies have confirmed these associations in a number of individuals (van Bon 
et al, 2009; Helbig et al., 2009; Miller et al., 2009; Ben-Shachar et al., 2009). It is long known 
that autism and other mental disorders share common symptoms with schizophrenia. The 
presence of a small number of individuals affected with these mental disorders in a large 
sample of thousands of cases affected with schizophrenia could lead to statistically 
significant results. Especially in large samples diagnostic uncertainty cannot always be 
completely excluded, and therefore, careful follow-up with functional studies on the results 
in schizophrenia would be prudent. Overall, research in schizophrenia points to the 
possibility of heterogeneity similar to results in rare Mendelian developmental disorders 
and complex X-linked mental retardation.    
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6. Discussion 
Finding genetic risk factors in common complex mental disorders is an area of intense 
research. Linkage studies, positional candidate gene sequencing approaches, as well as the 
search for truncating mutations that severely disrupt the function of a protein are traditional 
tools that have been applied successfully to rare Mendelian genetic syndromes leading to 
the identification of rare Mendelian variants. In common complex mental disorders, on the 
other hand, it has been the accepted hypothesis that different genetic risk factors might play 
a role. Common complex disorders are thought to involve common genomic variants 
present in at least one percent of the population. Genome-wide association studies have 
been designed to find few common risk variants that would explain the pathophysiology of 
common complex disorders. Even though these studies have been successful in identifying 
common variants with low associated risk in some disorders, it has to be admitted that the 
majority of cases still remains unexplained. This scenario leaves several open questions. 
Could it be that common complex disorders after all are not so different from rare 
Mendelian disorders? Could it be that the effect of the mutations involved is only less 
pronounced and easier to compensate? Could it be that common complex disorders are as 
heterogeneous as Mendelian disorders, as demonstrated in X-linked mental retardation? In 
this disorder close to hundred different genetic causes have been identified, each of which is 
individually rare. Nevertheless, the majority of cases still remains unexplained. Could 
psychiatric disorders such as bipolar disorder and schizophrenia be more heterogeneous 
with regard to their underlying pathophysiology and genetic risk factors than we ever 
would have imagined?  Could it be that these disorders are caused by many rare genetic 
mutations, some of which would be present in only a small number of families? The answer 
to these questions can only come from further research. However, even considering these 
scenarios would require different strategic approaches. It might be useful to reconsider 
proven technologies, such as positional candidate gene sequencing and family based studies 
in addition to large-scale genome-wide approaches. It could be useful to consider the 
possibility that collecting an ever-larger number of samples might only increase the 
heterogeneity of the cases. In the end it might be useful to refocus on the evaluation of 
functional consequences of mutations instead of being mesmerized by bio-statistical p-
values. The answer to these questions must remain unknown. The comparison of different 
research strategies in related fields might be instructive and inspiring. After all, mental 
retardation is about as frequent as psychotic disorders in the general population and 
developmental syndromes might actually be among samples of schizophrenia patients, 
since they often share symptoms of hallucinations and delusions. In the end, considering all 
possible approaches might be the way that will enhance our understanding of mental 
disorders. 
7. Conclusion 
As the focus in common complex mental disorders has shifted from hypothesis-based 
candidate gene approaches to genome-wide explorations, the focus might shift from 
common genomic variants to the detection of rare variants. Research strategies might adjust 
as well moving from genome-wide association studies of common variants to re-sequencing 
approaches of entire genomes. While this shift takes place it could be instructive to study 
some of the lessons learned from hypothesis driven re-sequencing approaches in 
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developmental disorders and chromosome-wide re-sequencing studies in X-linked mental 
retardation. Re-sequencing approaches have been successful in identifying new genes of 
unknown function, for which prior hypothesis did not exist before. On the other hand, 
follow-up and evaluation of the large amount of common and rare variants identified by 
this approach could be challenging. As genome-wide re-sequencing studies will most likely 
reveal a tremendous amount of genomic variants, hypothesis driven approaches might be 
very useful in follow-up of genome-wide sequencing approaches, particularly in a world of 
limited resources of time and money. Family-based re-sequencing approaches as compared 
to population-based approaches will allow detecting the segregation of the phenotype with 
the genotype. This might be a useful prerequisite for separating random noise of genomic 
variability from disease causing variants. Functional tests will in the end be required to 
ultimately inform about disease patho-physiology. Last but not least, rare and private 
mutations might be more commonly involved in disease pathology than we would have 
ever imagined.     
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